Scandinavian Journal of Immunology

Papers
(The H4-Index of Scandinavian Journal of Immunology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management192
Pattern of human monocyte subpopulations in health and disease106
Lymphopenia an important immunological abnormality in patients with COVID‐19: Possible mechanisms75
T cell immunobiology and cytokine storm of COVID‐1973
The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment55
Mechanism of fibrosis and stricture formation in Crohn's disease52
An inflammation classification system using cytokine parameters52
Advances in Neutralization Assays for SARS‐CoV‐240
Can medicinal mushrooms have prophylactic or therapeutic effect against COVID‐19 and its pneumonic superinfection and complicating inflammation?37
Current knowledge on autoantigens and autoantibodies in psoriasis37
Interactions between SARS coronavirus 2 papain‐like protease and immune system: A potential drug target for the treatment of COVID‐1930
SARS‐CoV‐2 infection‐induced immune responses: Friends or foes?30
Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy26
The potential involvement of P2X7 receptor in COVID‐19 pathogenesis: A new therapeutic target?26
Cold‐inducible RNA‐binding protein (CIRP) in inflammatory diseases: Molecular insights of its associated signalling pathways25
TLR10: Insights, controversies and potential utility as a therapeutic target25
The role of innate immunity and inflammation in Parkinson´s disease25
Mucosal chemokine CXCL17: What is known and not known24
A comparative review of intelectins24
Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: A systematic review23
Serum levels of soluble programmed death‐1 (sPD‐1) and soluble programmed death ligand 1(sPD‐L1) in systemic lupus erythematosus: Association with activity and severity23
Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma23
COVID‐19: Risk Factors Associated with Infectivity and Severity23
0.026037931442261